☰

Jason G. Harb, Ph.D.

Affiliations: 
2004 University of Wisconsin-Milwaukee, Milwaukee, WI 
Area:
Analytical Chemistry
Google:
"Jason Harb"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Joseph H. Aldstadt grad student 2000-2004 UW-Milwaukee
 (Development of novel analytical techniques and methods for the chemical and physical speciation of semi-volatile organic and inorganic compounds in environmental matrices.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Silvestri G, Stramucci L, Ellis J, et al. (2018) Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance Cancer Research. 78: 1134-1134
Silvestri G, Stramucci L, Ellis J, et al. (2015) Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML Blood. 126: 53-53
Silvestri G, Ellis J, Stramucci L, et al. (2014) MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay Blood. 124: 4529-4529
Neviani P, Harb JG, Oaks JJ, et al. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57
Walker CJ, Oaks JJ, Santhanam R, et al. (2013) Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44
Oaks JJ, Santhanam R, Walker CJ, et al. (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34
Harb JG, Neviani P, Chyla BJ, et al. (2013) Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 27: 1996-2005
Alachkar H, Santhanam R, Harb JG, et al. (2013) Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21
Magistroni V, Sharma N, Piazza R, et al. (2012) Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia Blood. 120: 3727-3727
Walker CJ, Oaks JJ, Santhanam R, et al. (2012) Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL Blood. 120: 35-35
See more...